Mpox study in guinea aims to unlock secrets of virus spread and vaccine power

NCT ID NCT07534267

Not yet recruiting Knowledge-focused Sponsor: London School of Hygiene and Tropical Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study in Guinea will follow about 992 people to understand how long the mpox virus stays in the body after infection, how it spreads to close contacts, and how well the MVA-BN vaccine protects against infection and disease. Researchers will collect samples and track participants for up to two months. The goal is to provide real-world data to help control mpox outbreaks in West Africa.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MVA-BN vaccine
What this could lead to: If successful, this could provide crucial data on mpox transmission and vaccine effectiveness in West Africa, helping to control future outbreaks.
What could go wrong: This is an observational study, not a treatment trial. Results depend on real-world conditions and may not apply to other regions. Vaccine effectiveness estimates may be limited by small sample sizes or incomplete follow-up.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MONKEYPOX are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

monkeypox

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MONKEYPOX MPOX (MONKEYPOX)

Contacts and locations

Locations

Centre National de Formation et de Recherche en Sante Rurale de Maferinyah

Conakry, Guinea

More trials for these conditions

Other studies related to the condition(s) this trial covers.